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Accepted 16 December 2015; Published online 21 December 2015AbstractObjectives: To assess the risk posed by missing data (MD) to the power and validity of trials evaluating palliative interventions.
Study Design and Setting: A systematic review of MD in published randomized controlled trials (RCTs) of palliative interventions in
participants with life-limiting illnesses was conducted, and random-effects meta-analyses and metaregression were performed. CENTRAL,
MEDLINE, and EMBASE (2009e2014) were searched with no language restrictions.
Results: One hundred and eight RCTs representing 15,560 patients were included. The weighted estimate for MD at the primary
endpoint was 23.1% (95% confidence interval [CI] 19.3, 27.4). Larger MD proportions were associated with increasing numbers of ques-
tions/tests requested (odds ratio [OR], 1.19; 95% CI 1.05, 1.35) and with longer study duration (OR, 1.09; 95% CI 1.02, 1.17). Meta-
analysis found evidence of differential rates of MD between trial arms, which varied in direction (OR, 1.04; 95% CI 0.90, 1.20; I2
35.9, P 5 0.001). Despite randomization, MD in the intervention arms (vs. control) were more likely to be attributed to disease progression
unrelated to the intervention (OR, 1.31; 95% CI 1.02, 1.69). This was not the case for MD due to death (OR, 0.92; 95% CI 0.78, 1.08).
Conclusion: The overall proportion and differential rates and reasons for MD reduce the power and potentially introduce bias to palli-
ative care trials.  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Missing data (MD) are defined as observations that
would be meaningful to analysis and are intended to be
made, but for some reason are not [1]. There are two types
of MD: unit, where no data are provided from a unit, for
example, participant; and item, where particular items of
data are not provided [2]. These can occur intermittently
or in a monotone pattern when no further data are provided.
Such MD reduce the power, precision, and, if certainNo conflicts of interest or financial disclosures to declare.
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4.0/).groups of participants (ie, those who have a poor perfor-
mance status) are missing, external validity of trial findings
[3]. Furthermore, MD can pose a major threat to the inter-
nal validity of trial results [3]. This can occur particularly if
there are significant differences between trial arms with re-
gards to: (1) rates of MD, (2) the baseline characteristics of
those who do not provide data, or (3) the reasons data are
missing. Such differences indicate that the trial arms are
no longer comparable for known and unknown factors,
and therefore, the scientific benefits of randomization are
compromised.
Trials of palliative interventions in participants with
advanced life-limiting illnesses present an important case
with regards to MD. Large amounts of MD due to death
and disease progression unrelated to the intervention ares article under the CC BY license (http://creativecommons.org/licenses/by/
linical Epidemiology 74 (2016) 57e65What is new?
 On average nearly a quarter of primary endpoint
data are reported as missing in trials evaluating
palliative interventions in participants with
advanced disease (95% prediction interval 11.8,
67.7).
 Both increasing numbers of questions asked and/or
tests requested and study duration were associated
with larger proportions of missing data (MD).
 There was evidence of differential rates and rea-
sons for MD between the intervention and control
arms, which may introduces bias.
 MD in the intervention arm were more likely to be
attributed to disease progression unrelated to the
intervention, compared to the control arm. This in-
dicates that there may be systematic misclassifica-
tion of the reason for MD.
expected in this population and do not necessarily reflect
poor trial design and conduct [4,5]. These MD will, howev-
er, reduce the power of the study to detect a true effect [3,5]
and potentially introduce bias if missingness is associated
with treatment allocation. It is therefore important that tri-
als are designed to minimize the extent of MD as much as
possible [3,4,6] and that an evidence-based estimate of the
proportion of MD is used to adjust the sample size for MD.
A review of participant-level data from 18 symptom control
palliative oncology studies from one center found the
average proportion of attrition by the primary endpoint
was 26% (95% confidence interval [CI] 23, 28%) [7]. How-
ever, it is unknown how this finding relates to a broader
enquiry encompassing single site and multisite trials, led
by different research centers, which evaluate a range of
palliative interventions in participants with malignant and
nonmalignant disease.
Inflation of the sample size to accommodate expected
MD will improve the power of a study; however, it will
not account for the bias caused by differential rates and rea-
sons for MD [3]. It is essential therefore to understand
which study design and participant factors are associated
with both the overall amount and differential rates of MD
and consequently how these can be minimized. Palliative
care encompasses a wide variety of life-limiting illnesses
and a broad range of pharmacological, psychological, and
spiritual interventions. Therefore, it is expected that the
rates of MD will vary considerably in this population, which
will enable factors associated with MD to be assessed.
This systematic review and meta-analyses assessed the
risk MD poses to trials testing palliative interventions.
The specific aims of the review were to determine (1) the
proportion of MD by the primary endpoint across a
58 J.A. Hussain et al. / Journal of Crepresentative range of published palliative care trials; (2)
trial design and participant factors associated with the over-
all proportion of MD at the primary end-point; (3) whether
there is evidence of differential rates of MD and which
study design factors are associated with this; (4) whether
the baseline characteristics and reasons for MD differ be-
tween trial arms, thus potentially introducing bias.2. Materials and methods
2.1. Eligibility criteria
Eligible studies were randomized controlled trials
(RCTs) published between January 2009 and April 2014,
that included adult participants with an advanced, progres-
sive, life-limiting illness, with no possibility of remission
[8]. Trials testing a palliative intervention where the pri-
mary aim is to improve quality of life, rather than modify
the disease process or improve survival, were included.
The nature of the intervention was not restricted, that is, tri-
als testing pharmacological, surgical, psychospiritual, and
communication skills interventions were eligible. Any com-
parators that were palliative in nature, standard care, or
placebo were included. This review was limited to trials
with patient-reported or patient-dependent primary out-
comes. If the primary outcome was the proportion of MD,
such studies were excluded. If the authors stated that the
trial arms were established by random allocation, that is,
the term ‘‘random(ized)’’ was used, then the study was
considered to be an RCT and included [9]. A 5-year period
was chosen to capture current practice and also overlapped
with the publication of the CONSORT 2010 statement [10]
which included clearer guidance on intention-to-treat (ITT)
analysis and the implications of MD than previous state-
ments. No language restrictions were applied.
2.2. Search strategy
An information specialist with the Pain, Palliative, and
Supportive Care Group (PaPaS) [11] at the Cochrane
Collaboration helped to formulate and conduct the search.
The electronic databases searched to identify studies were
CENTRAL (January 2009 to April 2014), OVID MED-
LINE (January 2009 to April 2014), and EMBASE
(January 2009 to April 2014). The search strategy com-
bined a modified version of the Cochrane PaPaS palliative
care search strategy [12] and the sensitivity maximizing
Cochrane Highly Sensitive Search Strategy for identifying
RCTs in MEDLINE [9] (see Appendix A at www.
jclinepi.com). Authors of studies were not contacted for
further studies because the aim was to provide a represen-
tative sample rather than to be exhaustive. To gain a repre-
sentative sample, a computer-generated random sequence
was used to select successive random samples of 100
studies, which were then screened until the a priori sample
size of over 100 trials was reached.
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Two reviewers independently and then in pairs conduct-
ed the screening, selection, and data extraction. One has a
background in palliative and health care research (J.A.H.)
and the other in statistics and clinical trials (D.L.), thus rep-
resenting both content and methodological expertise [13]. If
no agreement could be reached, an arbitrator was to be con-
sulted. Agreement was measured using kappa statistics for
categorical variables and intraclass correlation coefficient
(ICC) for continuous variables. If there was insufficient in-
formation to make a decision about inclusion, authors were
contacted via email and ResearchGate [14]. Studies pub-
lished in more than one article were combined into one
study.
2.4. Outcomes
In each study, the outcomes were (1) the proportion of
MD at the primary endpoint (analyzed as log odds), for
repeated measures where the time of the primary endpoint
was not clearly specified, the final observation was taken as
the primary endpoint; (2) differential rates of MD, defined
as the log odds ratio (OR) of MD in the intervention arm
compared to the control arm; (3) whether there were statis-
tically significant differences in baseline characteristics be-
tween the intervention and control arms; (iv) differential
reasons for MD, defined as the log ORs of missing due to
death, missing due to disease progression, and missing
due to toxicity, for the intervention arm compared to the
control arm. MD in this review included data censored
due to death and MD that could have been collected but
was not. If there were more than one intervention arm,
these were combined to represent all intervention arms;
therefore, the participants in the control arm were not used
to provide information on more than one effect size, thus
ensuring the information for the different estimates was in-
dependent [15].
2.5. Analysis
The DerSimonian and Laird random-effects model
(REM) meta-analysis was used for the proportion of MD
and differential rates and reasons for MD [16]. The Co-
chran Q (c2) test and the I2 statistic were used to analyze
statistical heterogeneity [17]. Cochran Q test has low power
when there are few studies or when included trials have a
small sample size; therefore, a priori a P-value  0.10
was considered to be statistically significant [17,18]. The
potential sources of heterogeneity were prespecified as
following:
A. Proportion of MD at the primary endpoint:
 ‘‘items of data requested’’: this is the total number
of individual questions and tests the participants
were required to complete during the course of
the trial time to the primary endpoint (days)
 total number of outcome measures and measure-
ment frequency
 nature and design of the trial; sample size; multi-
site/single site; funding source
 nature of the outcome, intervention, data collection
method, and setting
 exclusion of participants who are older, with a
poorer performance status or advanced disease
 use of specified methods to minimize MD
 trial participants’ average age, performance status,
and underlying disease
 risk of bias due to random sequence generation,
allocation concealment, and blinding
B. Differential rates of MD
 nature of the intervention and control
 blinding of participants
 items of data requested
 time to the primary endpoint (days).
All potential sources of heterogeneity were assessed in a
univariate metaregression analysis fitted by the residual
maximum likelihood method. The sources of heterogeneity
were further tested using the univariate and multivariate
Monte Carlo permutation test, which takes account of mul-
tiple testing (1,000 permutations per analysis) [19]. The
assumption of normality of the random effect for the meta-
regression model was assessed using a normal probability
plot of the standardized predicted random effects, which
demonstrated that the assumption was adequate. Analyses
were conducted using Comprehensive Meta-Analysis v2.2
and STATA v13. For all analyses, except those specified,
the level of statistical significance was set at 5%.3. Results
3.1. Study selection
Of the 1,923 titles and abstracts screened, 1,744 did not
meet the inclusion criteria. Full-text articles of 179 studies
were assessed for eligibility of which 108 were included in
the final analysis (Figure 1) and represented data from
15,560 randomized patient participants. For four articles,
full-texts were not available from authors or local and na-
tional libraries [20e23]; these are listed as ‘‘potentially
relevant studies’’ (see Appendix B at www.jclinepi.com).
Interrater agreement for categorical and continuous vari-
ables ranged from kappa statistic 0.64e1.0 and ICC
0.70e0.95; consultation with an arbitrator was not
required.
3.2. Study characteristics
The demographics of the included studies and partici-
pants are presented in Table 1. Most were parallel trials
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Additional records identified 
through other sources 
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1 Retention rate was primary outcome 
2 Primary outcome was not patient dependent 
9 Not a randomised controlled trial 
3 Primary analysis of trial not presented/post-hoc 
analysis 
14 Time to event study 
1 Protocol not trial data 
12 Duplicate study/data 
5 Conference abstract 
4 Unable to access full paper/abstract (authors 
emailed) 
1 Editorial/opinion piece/review 
Fig. 1. PRISMA study flow diagram.
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(73.1%). The mean age was 64 years, and average Eastern
Cooperative Oncology Group performance status was 2
(defined as ‘‘ambulatory and capable of self-care but unable
to carry out any work activities. Up and about forO50% of
waking hours’’ [24]). The median individual number of
questions asked/test requested was 106 (interquartile range
[IQR], 37e231) and time to the primary endpoint was
28 days (IQR, 7e84).3.3. Proportion of MD on the primary endpoint
The weighted summary estimate for the proportion of
MD on the primary endpoint was 23.1% (95% CI 19.3,
27.4; Figure 2). Fifty-six trials (51.9%) had greater than
20% MD on the primary endpoint. The majority of trials re-
ported MD due to attrition only; item-level MD were only
partially reported in 14 trials (13%). Heterogeneity was
very large with I2 5 96.0% and P ! 0.001. Tau2 was
1.2, which yields a 95% prediction interval of approxi-
mately 11.8 to 67.7, meaning the true proportion of MD
in the next study is expected to fall anywhere between
11.8% and 67.7%. This large range reflects theheterogeneity between studies and the error in estimating
the mean (which is minimized with the large sample size).
The high heterogeneity enabled an exploration of the
relationship between the proportion of MD and study-
level covariates using metaregression analysis (see
Appendix C at www.jclinepi.com for the results of all cova-
riates tested). Four variables had a statistically significant
association with the proportion of MD: (1) items of data re-
quested (OR, 1.27; 95% CI 1.13, 1.42, per doubling), (2)
time to the primary endpoint (OR, 1.13; 95% CI 1.06,
1.21, per doubling), (3) type of outcome (with most MD
for quality of life outcomes), and (4) whether participants
were excluded based on their: age/performance status/
extent of disease (OR, 1.65; 95% CI 1.08, 2.52; Table 2).
All four variables were assessed in a multivariate meta-
regression, and only (1) total items of data requested
(P 5 0.007) and (2) time to primary endpoint (P 5 0.02)
had a statistically significant association with the propor-
tion of MD, whereas variables (3) type of outcome and
(4) exclusion based on age/performance status/extent of
disease appeared to lose statistical significance because of
their association with the items of data requested and time
to primary endpoint (data not shown). All results were
Table 1. Demographics of included studies and participants
Trial demographics Number (%) Participant demographics Frequency or average (%)
Study design Number randomized Median 68
IQR 36e129
Parallel trials 94 (87) Age of intervention group Mean 64.5, SD 8.5
Range 30e85
Crossover trials 10 (9.3) Age of control group Mean 64.3, SD 8.5
Range 30e86
Cluster trials 4 (3.7) Life-limiting condition
Nature of trial Malignant disease 80 (74)
Feasibility 8 (7.4) Nonmalignant disease 6 (5.6)
Pilot 15 (13.9)
Phase 2 12 (11.1)
Phase 3 7 (6.5) Mixed 21 (19.4)
RCTa 66 (61.1) Not reported 1 (0.9)
Multicenter or single center Performance status (ECOG)
Single 63 (58.3) 0 1 (0.9)
Multiple 44 (40.7) 1 13 (12.0)
Unclear 1 (0.9) 2 18 (16.7)
Number of centers in multicentre trials Median 3, range 2e27 3 12 (11.1)
Continents 4 5 (4.6)
Europe 41 (38.0) Others: 0e2b 1 (0.9)
North America 38 (35.2) 0e3b 2 (1.9)
Asia 18 (16.7) KPS O50 1 (0.9)
Australia 6 (5.6) Not reported 55 (50.9)
Africa 2 (1.9) Median survival Median 118 days
IQR 67e192
O1 country 3 (2.8) Not reported 73 (67.6)
Abbreviations: IQR, interquartile range; RCT, randomized controlled trial; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky perfor-
mance status.
a Allocation explicitly described as a variant of the term ‘‘random’’ but not described as a feasibility, pilot, phase 2 or phase 3 trial.
b Performance status presented as a range.
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adjust for multiple testing (Table 2). The adjusted R2 was
21.0%; however, the residual I2 remained high at 95.4%.
These results demonstrate that the odds of MD increased
as the number of items of data requested and the number
of days to the primary endpoint increased (Table 2). For
the items of data requested, when the time to primary
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Fig. 2. Forest plot of the reported proportion of missing data at the pri-
mary endpoint.questions/tests requested is doubled, the MD OR increased
by 1.19. For the time to the primary endpoint, when the
number of questions/tests are constant, if the time to the
primary endpoint doubles, the MD OR increased by 1.09.3.4. Differential rates of MD
The median proportion of MD by the primary endpoint
in the intervention arm was 21.6% (IQR, 6.5e45.1%) and
in the control arm 20.0% (IQR, 3.8e41.8%). Meta-
analysis of the log OR of the proportion of MD in the inter-
vention compared to the control arm, resulted in an overall
OR of 1.04 (95% CI 0.90, 1.20) with highly significant sta-
tistical heterogeneity (I2 35.9, P 5 0.001; Figure 3). This
demonstrates that there is evidence of differential rates of
MD between the trial arms, which varies in direction across
trials.
The univariate and multivariate metaregression demon-
strated there was insufficient evidence of a significant asso-
ciation between the differential rate of MD between trial
arms and any of the prespecified factors tested: (1) nature
of the intervention (P 5 0.7), (2) nature of control
(P 5 0.2), (3) whether participants were blinded
(P 5 0.09), (4) items of data requested (P 5 0.4), and
(5) time to the primary endpoint (P 5 0.4; see Appendix
D at www.jclinepi.com).
Table 2. Univariate and multivariate metaregression for the odds ratio of missing data at the primary endpoint
Type of analysis Covariates Odds ratio P-value Confidence intervals Adjusted P-valuea
Univariate regression Items of data requested (per number of items doubling) 1.27 !0.001 1.13e1.42 !0.001
Time to primary endpoint (per number of days doubling) 1.13 0.001 1.06e1.21 !0.001
Type of outcome 0.02 db
Symptomc 1.00 d d
Psychospiritual 1.14 0.7 0.61e2.16
Quality of life 1.91 0.04 1.02e3.57
Other 0.60 0.06 0.36e1.01
Exclude patients based on age/performance status/
extent of disease
1.65 0.02 1.08e2.52 0.03
Multivariate regression Items of data requested (per doubling number of items) 1.19 0.007 1.05e1.35 0.02
Time to primary endpoint (per doubling number of days) 1.09 0.02 1.02e1.17 0.008
Multivariate model P ! 0.001, adjusted R2 21.0%, I2 residual 5 95.4%, Tau2 0.6.
a Adjusted for multiple testing (Monte Carlo permutation test).
b Not possible to determine.
c Reference category.
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Even if the proportion of MD in the trial arms is the
same, if different types of people have MD in the different
arms, this has the potential to introduce bias. No trial report
reported a comparison of the baseline characteristics of
those who withdrew from the intervention and control arms.
There was no evidence of a difference in the proportion of
MD due to death in the intervention arms compared to the
control arms, across the trials (OR, 0.92; 95% CI 0.78,
1.08; Table 3). The heterogeneity in the trials was low,
and there was no evidence of statistically significant vari-
ability between trials (I2 5 0.0, P 5 0.6).
The estimate of the OR of those who had MD due to dis-
ease progression unrelated to the intervention was 1.31
(95% CI 1.02, 1.69; Table 3). This suggests that those in
the intervention arm were significantly more likely to have
MD that were attributed to disease progression, compared
to those in the control arm. The I2 was 0.0 with no evidence
of statistically significant heterogeneity (P 5 0.9).
The number of trials that reported intervention related
adverse effects (including toxicity) in the intervention andFig. 3. Forest plot of the reported differential proportion of missing
data in the intervention compared to the control arm.control arm was smaller than for the other categories
(n 5 15). The estimate of the OR of those who had MD
attributed to adverse effects was 2.35 (95% CI 1.44, 3.86)
with little heterogeneity between trials (I2 5.0%, P 5 0.4;
Table 3). This indicates, as anticipated, that significantly
more participants had MD due to treatment-related adverse
effects in the intervention arm compared to the control arm.4. Discussion
The development of a robust evidence base for individ-
uals with advanced life-limiting illnesses that require palli-
ative interventions is a key priority for patients, clinicians,
and policy makers [25,26]. This systematic review and
meta-analyses demonstrates that on average, nearly a
quarter of data are missing by the primary endpoint in trials
evaluating palliative interventions in participants with
advanced disease. This reduces the power and precision
of trial results if not taken into account in the original po-
wer calculation and moreover can introduce systematic er-
ror through differential rates and reasons for MD. Such
potentially biased results may have significant conse-
quences for patient care subsequently informed by this
evidence.Table 3. Meta-analysis comparing the reasons for missing data in the
intervention compared to the control trial arms
Reason for missing data Death Disease progression Adverse effects
Number of trials 57 39 15
Point estimate 0.92 1.31 2.35
Lower limit 0.78 1.02 1.44
Upper limit 1.08 1.69 3.86
Cochran Q 51.8 26.3 14.7
DF 56 38 14
P-value 0.6 0.9 0.4
I2 0.0 0.0 5.0
Tau2 0.0 0.0 0.05
Abbreviation: DF, Degrees of freedom.
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nal and external validity of a trial, levelsO20% are consid-
ered to pose a significant risk [27]. In this review, the
weighted summary estimate for the proportion of MD by
the primary endpoint was 23.1% (95% CI 19.3, 27.4%),
similar to the proportion estimated in a review of 18
palliative-oncology trials [7]. As the trials were signifi-
cantly heterogeneous, compared to the 95% CI, the 95%
prediction interval (11.8, 67.7) more accurately describes
the full uncertainty around the summary estimate in a
way that acknowledges heterogeneity and can be applied
in sample size calculations in future trials [28].
Over 50% of trials had O20% of data missing for the
primary endpoint. This is much larger than the proportion
calculated in three systematic reviews of trials published
in general medical journals, which found the median pro-
portion of MD to be 6% [29], 9% [30], and 10% [31].
The proportion reported in this review is also likely to be
an underestimate as all but 14 trials only reported MD
due to attrition (unit level); item-level MD were not re-
ported systematically.
Our review assessed the burden of the trial in terms of the
number of individual questions asked/tests requested, total
number of outcomes, frequency of outcome measurement,
method and setting of data collection, type of intervention
and outcome, and duration. Only duration and the number
of individual items of data collected had a statistically sig-
nificant association with the proportion of MD. A review
of palliative oncology trials also found duration to be asso-
ciated with attrition at the primary endpoint (P 5 0.04) and
the end of the study (P 5 0.01) [7]. They also found trials
set in outpatients departments were significantly more likely
than inpatients to have attrition (P 5 0.05) [7]. Our large
systematic review however did not find sufficient evidence
of an association between the setting of the trial and MD
(see Appendix C at www.jclinepi.com). Both the duration
to the primary endpoint and number of individual items of
data requested must be considered in the design of a trial,
and if the research question and science necessitates that
they cannot be minimized, adequate resources must be pro-
vided to ensure participants are supported to provide the
outcome data. Together the two factors only explained
21% of the variance, which suggests other mediating factors
need exploration.
There was evidence of differential rates of MD between
intervention and control arms, which varied in direction.
This suggests that there is a significant risk that the MD
in these trials may introduce bias, and the direction of bias
varies. Other reviews of differential rates of MD across a
range of health care disciplines have reported mixed results
[32e37], with half reporting no evidence of differential
attrition [32e34]. There was insufficient evidence that
any of the prespecified covariates explained the heterogene-
ity, although the risk of bias associated with participant
blinding was approaching statistical significance at the
5% level (P 5 0.09). Crutzen et al. [35] in their reviewof health behavior change trials also did not find any
explanatory variables to be significantly associated with
the rate of differential attrition. However, an RCT of a psy-
chosocial intervention on well-being after colorectal cancer
surgery did find the probability of nonresponse decreased
with increasing anxiety in the intervention group but
increased with increasing anxiety in the control group
[38]. These findings indicate that further exploration of fac-
tors that predict differential rates of MD is required.
Although the imbalances in the differential rates of over-
all MD varied across trials, imbalances for specific reasons
for MD were found to be homogeneous. There was no evi-
dence that the proportion of participants who died in the
intervention compared to the control arms was significantly
different after randomization. This is expected in RCTs
testing interventions that are palliative and do not aim to
improve survival, in a population where death unrelated to
the intervention is expected. However, this was not the case
for MD due to disease progression unrelated to the interven-
tion (OR, 1.31; 95% CI 1.02, 1.69). In a population where
disease progression unrelated to the intervention is ex-
pected, this is a surprising finding, as we would expect that
through randomization, on average, both groups would be
balanced in this regard. Some of the interventions may have
had a survival advantage as a secondary gain, but the results
indicate that more of the participants in the intervention
arms withdrew because of disease progression. In the
context of an adequately randomized trial, this can only
be explained by a postrandomization effect and indicates
strongly that there is systematic misclassification of the rea-
sons for MD. A possible explanation is that intervention-
related adverse effects are misattributed to disease progres-
sion unrelated to the intervention, thus underestimating the
harm of interventions.4.1. Limitations
Palliative care is an evolving, diffuse field, which spans
multiple subject areas [39], with research published in
specialist palliative care and general medical journals.
The identification of relevant literature therefore is prob-
lematic, and eligible trials may have been missed. To
address this, we used previously validated search strategies
for both palliative care and RCTs and accessed the support
of an information specialist. Four [40e43] potentially rele-
vant reports were not included as the full text could not be
retrieved from local and national libraries or authors. As
with any systematic review that only includes published
research, there is a risk of publication bias, multiple publi-
cation bias, and reference bias [44]. The inclusion of pub-
lished trials will also likely present an overoptimistic
picture of the impact of MD in palliative care trials.
Furthermore, we included data censored because of death
in our definition of MD; however, this presents a different
issue to MD in those alive [45,46]. However, as all incom-
plete data impacts the interpretation of trial results, in this
64 J.A. Hussain et al. / Journal of Clinical Epidemiology 74 (2016) 57e65exploratory review a priori it was considered important for
this to be quantified and assessed.5. Conclusions
The average proportion of MD by the primary endpoint
in palliative care RCTs is large and presents a significant
risk to the power, precision, and generalizability of trial
results. The minimization of MD is therefore essential,
and this systematic review indicates that both the trial
burden and duration need to be considered in trial design
and sample size adjustment for MD. Further research is
required to generate a theoretical framework to explain
why MD occurs in these trials and in particular why differ-
ential rates of MD occur. This will help inform researchers
on how to best reduce MD that is modifiable in this popu-
lation as recommended in MD guidance [3,4,47]. Such
marginal gains could have a significant impact on trial val-
idity [48]. No trials compared the baseline characteristics of
participants who had MD, but this information is important
in the assessment of the risk of bias and should routinely be
reported. Further research is also required into how the rea-
sons for MD are assessed and documented, especially when
differentiating MD due to disease progression and adverse
effects in this population.Acknowledgments
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